Results 171 to 180 of about 162,344 (301)
CTSC Confers Radioresistance in Hepatocellular Carcinoma by Regulating Myeloid-Derived Suppressor Cells. [PDF]
Xu J +5 more
europepmc +1 more source
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu +18 more
wiley +1 more source
CD55-expressing myeloid-derived suppressor cells (MDSCs) drive cancer immunoevasion. [PDF]
Jiang X +16 more
europepmc +1 more source
Identifying Cytokine Motif‐Containing, Immunomodulatory Bacterial Proteins in Human Gut Microbiome
By building and constructing HMM (Upper left, blue), the authors identify CMCPs in bacteria genomes and CRC related metagenomes and enriched CRC‐related CMCPs (Upper right, blue). They analyze sequence and structural similarity of hits (Lower left, green), test function with engineered EcN delivered to tumors in a mouse tumor model (Lower right, pink ...
Ziyu Wang +12 more
wiley +1 more source
The m6A reader YTHDF1 drives intrahepatic cholangiocarcinoma (ICC) progression by remodeling the tumor immune microenvironment. YTHDF1 promotes MDSC recruitment via activation of m6A‐FOSL2‐CXCL6/CXCR2 axis, thereby suppressing CD8+ T cell infiltration and function.
Li Luo +14 more
wiley +1 more source
Myeloid derived suppressor cells in neuroblastoma: mechanisms of immune evasion and therapeutic opportunities. [PDF]
Choo HS, Yu T, Pham T, Singh N, Joshi S.
europepmc +1 more source
Macrophage Extracellular Traps in Immunity and Cancer
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li +5 more
wiley +1 more source
Drug Delivery Systems for Resiquimod to Control Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. [PDF]
He Y, Yeo Y.
europepmc +1 more source
Schematic illustration of the synthesis protocol for Fe‐SH@Fn, an AML‐targeted nanoplatform engineered to co‐deliver shikonin (SH) and Fe3+, synergistically boosting antitumor immunity via ferroptosis induction and immunogenic cell death (ICD). ABSTRACT Acute myeloid leukemia (AML) remains a therapeutic challenge due to its low immunogenicity and ...
Shangqin Yang +9 more
wiley +1 more source

